CClinicalTrials.gg
RecruitingNCT01293214Updated Oct 1, 2026

Vascularized Composite Allotransplantation for Multiple Extremity Amputations

An interventional study of Limb transplantation in Limb Amputation and Extremity Amputation, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2010, registered Feb 2011).
  • Started Feb 2010; still recruiting 16 years 8 months later.
Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Limb transplantation surgery is the transfer of one or more limbs from a deceased human donor to a patient with single or multiple limb amputation. Hand transplantation is an innovative reconstructive procedure that has the potential to significantly improve the lives of hand amputees. The purpose of this study is to develop the best practices for multiple limb transplantation that will improve the outcomes of future limb transplant recipients.

Read the detailed description

Limb transplantation surgery, the transfer of the limb(s) from a deceased human donor to a patient with amputation of one or more limbss, is an experimental reconstructive procedure that has the potential to significantly improve the lives of amputees.

Limb transplantation is similar to face transplantation in that the tissues transplanted include skin, tendons, muscles, ligaments, bones and blood vessels. The transplant team at Brigham and Women's Hospital includes a wide variety of medical and surgical specialties. The team hopes to build upon the success of their first face transplantation to provide amputee patients with the significant benefits of limb transplantation.

Toward this goal, BWH is actively seeking qualified candidates for the limb transplant research study. We will be studying a small group of people to learn more about:

  • How to advance the science of limb transplantation
  • How to support and limit transplant rejection issues
  • How people do after limb transplantation

We describe limb transplant surgery as a life-giving procedure because it has the potential to dramatically improve, that is to restore, both a patient's mental and physical health and his/her ability to function and integrate in society. However, as with any other type of organ transplantation, this improvement will require the patient to make a lifetime commitment to taking medications that suppress the body's immune system.

Conventional reconstruction methods are always considered first, but they may provide less than optimal results for certain patients. There are many sophisticated prostheses that satisfactorily replace the basic function of a missing limb. However, replacing limbs (in whole or in part) with prosthetics remains suboptimal in that prostheses do not provide sensation and do not have a natural appearance. Limbtransplant surgery, however, has the potential to deliver these desired functional and aesthetic benefits. Functionally, limb transplant surgery can provide a patient with new limbs that, after extensive rehabilitation, allow him/her to perform daily activities and, in most cases, return to work. Furthermore, the ability to restore a near-normal aesthetic appearance of the limb(s) can lead to tremendous psychological benefits, including elevated confidence and mood.

From the time we begin our search for a qualified limb transplant recipient to the continuing care we provide following surgery, a significant amount of time, expertise and attentiveness is contributed toward making the procedure a progressive success. Limb transplant candidates go through an extensive screening process that is likely to last several months. This screening includes a psychiatric and social support evaluation and a series of imaging tests to help determine a patient's physical and mental readiness for the procedure. If, upon completion of the screening process, it is determined that a patient is a suitable candidate, we will place the patient on a transplant waiting list. We will then begin working with the New England Organ Bank (NEOB) team to find a donor who matches the recipient's tissue requirements - for example similar age and correct blood type. This search could take many months, and, if a suitable donor is not found within one year, we will speak with the patient to determine whether he/she is willing to continue waiting.

02

Conditions studied

  • Limb Amputation
  • Extremity Amputation

Keywords

  • limb transplantation
  • limb allotransplantation
  • hand transplantation
  • hand allotransplantation
  • hand amputation
  • leg transplantation
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 18 and 60 years.
  • Single dominant hand or multiple limb amputation.
  • Time elapsed since amputation more than 6 months but less than 15 years.
  • Patient has tried prosthesis without success.
  • Level of amputation anywhere from the wrist (or ankle) joint to just below the shoulder (or hip) joint, which should be functional.
  • Signed written informed consent.
  • Willing to complete psychological and social evaluations.
  • Willing to take immunosuppressants - drugs that help prevent rejection of the transplant - for life.
  • Willing to comply with extensive post-transplant rehabilitation for a minimum of two years.
  • Willing to return for follow-up visits as determined by the treating physician.
  • Willing to receive standard vaccinations prior to the transplant, such as influenza and hepatitis B.

Exclusion criteria

Exclusion Criteria:

  • Single, non-dominant hand amputees.
  • Active malignancy.
  • High risk of return of malignancy.
  • History of persistent non-compliance.
  • Findings of psychological evaluation that indicate inability to comply with physician's orders or mental instability.
  • Any diagnosis that puts the subject at risk from limb transplant surgery or life-long immune suppression.
  • Inability to ensure adequate follow-up of post-transplant care and immune suppression.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Transplantation

    Subjects will undergo single or multiple limb transplantation

    Procedure: Limb transplantation

Interventions

  • ProcedureLimb transplantation

    Also known as: vascularized composite allotransplantation

06

What researchers measure

Primary outcomes

  1. Outcomes of limb transplantation

    We will undertake an objective evaluation of the results of limb transplantation in an "outcome-oriented" study

    Time frame: Subjects will be followed for 18 months after transplantation

Secondary outcomes

  1. Efficacy and optimization of the immune suppression protocol

    We will evaluate the risks of rejection or likelihood of tolerance induction by measuring specific parameters in the blood or tissue, including: Serum alloantibodies concentration, numbers/phenotype of specific T cell alloreactivity in the peripheral blood, phenotypic characterization of graft infiltrating cells and local gene expression of cells and cytokines.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
08

References and documents

Publications

  • Pomahac B, Aflaki P. Composite tissue transplantation: a new era in transplantation surgery. Eplasty. 2010 Sep 15;10:e58. PubMed 20862294 ↗
  • Bueno E, Benjamin MJ, Sisk G, Sampson CE, Carty M, Pribaz JJ, Pomahac B, Talbot SG. Rehabilitation following hand transplantation. Hand (N Y). 2014 Mar;9(1):9-15. doi: 10.1007/s11552-013-9568-8. PubMed 24570631 ↗
  • Carty MJ, Zuker R, Cavadas P, Pribaz JJ, Talbot SG, Pomahac B. The case for lower extremity allotransplantation. Plast Reconstr Surg. 2013 Jun;131(6):1272-1277. doi: 10.1097/PRS.0b013e31828bd1a5. PubMed 23416434 ↗
  • George E, Mitsouras D, Kumamaru KK, Shah N, Smith SE, Schultz K, Deaver PM, Mullen KM, Steigner ML, Gravereaux EC, Demehri S, Bueno EM, Talbot SG, Pomahac B, Rybicki FJ. Upper extremity composite tissue allotransplantation imaging. Eplasty. 2013 Jul 16;13:e38. eCollection 2013. PubMed 23943677 ↗
  • Borges TJ, Abarzua P, Gassen RB, Kollar B, Lima-Filho M, Aoyama BT, Gluhova D, Clark RA, Islam SA, Pomahac B, Murphy GF, Lian CG, Talbot SG, Riella LV. T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation. Cell Rep Med. 2022 Mar 15;3(3):100559. doi: 10.1016/j.xcrm.2022.100559. eCollection 2022 Mar 15. PubMed 35492875 ↗
09

Updates

1 registry update since Sep 25, 2026
Primary completion
Dec 31, 2026→Dec 31, 2030
Oct 1, 2026
Study completion
Dec 31, 2026→Dec 31, 2030
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Dec 31, 2026→Dec 31, 2030
    Study completion Dec 31, 2026→Dec 31, 2030
    + 5 other changes: verification date, oversight details, contact details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01293214
Lead sponsor
Brigham and Women's Hospital
Responsible party
Simon George Talbot (Director, Upper Extremity Transplant Program, Brigham and Women's Hospital) — Principal investigator
First posted
Feb 10, 2011
Start date
Feb 1, 2010
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion